World's Best Scientists 2026 revealed!
Ronald Herbst

Ronald Herbst

D-Index & Metrics

Immunology

D-Index
51
Citations
11698
World Ranking
4130
National Ranking
31

Overview

Ronald Herbst is affiliated with Biolojic Design in Israel. Their research primarily focuses on medicine, with significant contributions to the fields of immunology and microbiology. Within these areas, Herbst has explored subfields such as immunology, oncology, infectious diseases, molecular biology, and neurology.

Their work addresses several main topics, including:

  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • CAR-T Cell Therapy Research
  • Tuberculosis Research and Epidemiology
  • Atherosclerosis and Cardiovascular Diseases
  • T-cell and B-cell Immunology
  • Cytokine Signaling Pathways and Interactions

Herbst has published articles in a number of scientific journals, with frequent appearances in:

  • Clinical Cancer Research
  • Cancer Discovery
  • Molecular Cancer Therapeutics
  • Communications Biology
  • Cancer Immunology Research

Notable recent papers authored or co-authored by Herbst include:

  • Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment, 2020, Clinical Cancer Research
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown, 2021, Cancer Discovery
  • Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR, 2021, Molecular Cancer Therapeutics
  • Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction, 2022, Communications Biology
  • Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1, 2021, Cancer Immunology Research

Throughout their career, Herbst has collaborated frequently with several researchers, including:

  • Kathy Mulgrew
  • Philip Martin
  • Andrew Garcia
  • Gianluca Carlesso
  • Susannah L. Hewitt

Best Publications

  • HMGB1 and RAGE in inflammation and cancer.

    Gary P. Sims;Daniel C. Rowe;Svend T. Rietdijk;Ronald Herbst

  • Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

    Pascale André;Caroline Denis;Caroline Soulas;Clarisse Bourbon-Caillet

  • Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

    Heng Lin;Shuang Wei;Elaine M. Hurt;Michael D. Green

  • The Immunoscore: Colon Cancer and Beyond

    Helen K. Angell;Daniela Bruni;J. Carl Barrett;Ronald Herbst

  • TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

    Jerome Biton;Jerome Biton;Audrey Mansuet-Lupo;Nicolas Pécuchet;Marco Alifano

  • Targeting CD73 in the tumor microenvironment with MEDI9447

    Carl M. Hay;Erin Sult;Qihui Huang;Kathy Mulgrew

  • Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.

    Liyan Jiang;Jiaqi Huang;Brandon W. Higgs;Zhibin Hu

  • Kinesin motor proteins as targets for cancer therapy

    Dennis Huszar;Maria-Elena Theoclitou;Jeffrey Skolnik;Ronald Herbst

  • Retraction Note: Microglia-dependent synapse loss in type I interferon-mediated lupus.

    Allison R. Bialas;Jessy Presumey;Abhishek Das;Cees E. van der Poel

  • Cell Distance Mapping Identifies Functional T Follicular Helper Cells in Inflamed Human Renal Tissue

    Vladimir M. Liarski;Natalya Kaverina;Anthony Chang;Daniel Brandt

  • Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

    Unknown

  • B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase.

    Sarah L. Pogue;Tomohiro Kurosaki;Joseph Bolen;Ronald Herbst

  • Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

    Stefanie R. Mullins;John P. Vasilakos;Katharina Deschler;Iwen Grigsby

  • Self-reactive IgE exacerbates interferon responses associated with autoimmunity

    Jill Henault;Jeffrey M Riggs;Jodi L Karnell;Vladimir M Liarski

  • B cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody

    Ronald Herbst;Yue Wang;Sandra Gallagher;Nanette Mittereder

  • MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis

    Wen Pan;Shu Zhu;Dai Dai;Zheng Liu

  • CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

    Ralph F. Alderson;Robert J. Kreitman;Tianling Chen;Peter Yeung

  • The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

    Diane Damotte;Sarah Warren;Jennifer Arrondeau;Pascaline Boudou-Rouquette

  • IL-22 Increases Permeability of Intestinal Epithelial Tight Junctions by Enhancing Claudin-2 Expression

    Yaya Wang;John Brian Mumm;Ronald Herbst;Roland Kolbeck

  • S100A9 Induced Inflammatory Responses Are Mediated by Distinct Damage Associated Molecular Patterns (DAMP) Receptors In Vitro and In Vivo

    Bo Chen;Allison L. Miller;Marlon Rebelatto;Yambasu Brewah

  • B-cell targeted therapeutics in clinical development

    Stephan Blüml;Kathleen McKeever;Rachel Ettinger;Josef Smolen

  • Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

    Melissa Damschroder;Peter Kiener;Herren Wu;William Dall'acqua

Frequent Co-Authors

Herren Wu
Herren Wu AstraZeneca (United Kingdom)
Peter A. Kiener
Peter A. Kiener AstraZeneca (United Kingdom)
Anthony J. Coyle
Anthony J. Coyle Takeda (United States)
Roland Kolbeck
Roland Kolbeck AstraZeneca (United Kingdom)
Isabelle Cremer
Isabelle Cremer Sorbonne University
Michael C. Carroll
Michael C. Carroll Boston Children's Hospital
Thomas F. Tedder
Thomas F. Tedder Duke University
Guy Brusselle
Guy Brusselle Ghent University Hospital
Bart N. Lambrecht
Bart N. Lambrecht Ghent University
Ken R. Bracke
Ken R. Bracke Ghent University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring complementary healthcare degrees can open diverse career opportunities. Many students transition into nursing roles to gain practical experience with patient care and clinical applications of immunological principles.

For example, accelerated pathways such as accelerated fnp programs offer a fast-track to becoming a Family Nurse Practitioner, integrating immunology knowledge in diagnosing and treating patients.

Individuals without prior nursing education may consider online rn programs for non nurses, which provide flexible and accessible options to begin nursing careers while enhancing their science foundation.

For those entering nursing through a bachelor’s degree, selecting the easiest absn program to get into can reduce admission barriers and shorten the pathway to clinical practice.

Additionally, becoming a Licensed Practical Nurse through programs with lpn programs with easiest admission requirements can be a practical stepping stone, offering hands-on experience related to immune system care in various healthcare settings.

Best Scientists Citing Ronald Herbst

Trending Scientists

Recently Published Articles